Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT02987855 Withdrawn - Fibromyalgia Clinical Trials

Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia

ADcSVF-CRPS
Start date: December 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and Fibromyalgia represent progressive systemic pain conditions which often worsen over time. They appear to be dysregulation of the central nervous system (CNS) and the autonomic system (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and disabilities. They are often associated with injury sites (including surgical) which produce constant, often disabling pain and motor-sensory losses. Treatments are often ineffective and include medications (often high dose opiates), Physical Therapy (PT), and surgical interventions (sympathectomy, ablation) or insertion stimulators of the CNS. Study is an interventional study to document the safety and efficacy of use of adipose-derived cellular stromal vascular fraction (AD-cSVF) in chronic pain and dysfunction disease groups.

NCT ID: NCT02986451 Withdrawn - Clinical trials for Relapse/Refractory Multiple Myeloma

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Start date: December 2016
Phase: Phase 2
Study type: Interventional

This phase II study investigating the efficacy and safety of a combination of biaxin,lenalidomide and dexamethasone in subjects with relapsed/refractory MM.

NCT ID: NCT02985333 Withdrawn - Clinical trials for Relapse/Refractory Multiple Myeloma

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple myeloma.

NCT ID: NCT02985177 Withdrawn - Acute Pain Clinical Trials

A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture

CAST
Start date: January 2020
Phase: Phase 4
Study type: Interventional

MSK-I is the most common cause for ED visits for children with pain, with a child's risk of sustaining a fracture ranging from 27-42% by the age of 16 years. MSK-I is known to generate moderate to severe pain in most children and the ED serves as the critical entry point for these injured children. This study aims to provide rapid and sustained pain management for children presenting with a MSK-I in the ED. The investigators will compare the efficacy of two possible medication combinations of fentanyl intranasal (1.0 mcg/kg) + oral ibuprofen (10 mg/kg) and fentanyl intranasal (2.0 mcg/kg) + oral ibuprofen (10 mg/kg) for the rapid, adequate and sustained pain management of children with suspected fracture. The investigators believe that the combination of different dosage of intranasal fentanyl with ibuprofen will lead to better pain treatment by providing a consistent and adequate level of analgesia throughout the entire ED visit, including prior to physician exam and during painful radiologic procedures.

NCT ID: NCT02977039 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus in Obese

Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity

Start date: November 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of a nutrient dense plant rich (NDPR) diet compared to a standard USDA diet on glycemic control, inflammation, and cardiovascular risk in individuals with type 2 diabetes and overweight/obesity.

NCT ID: NCT02975921 Withdrawn - Pleural Effusion Clinical Trials

Betadine Pleurodesis Via Tunneled Pleural Catheters

Start date: July 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether betadine (povidone-iodine) instillation during routine indwelling Tunneled Pleural Catheter (TPC) placement is efficacious in promoting pleurodesis and thus reducing the time to TPC removal.

NCT ID: NCT02975570 Withdrawn - Clinical trials for Tuberculosis Multi Drug Resistant Active

Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin

DAZZLE
Start date: August 2017
Phase: Phase 3
Study type: Interventional

The proposed study will randomize adults (18 years of age or older) with pulmonary MDR-TB with sputum that contains M. tuberculosis that is isoniazid and rifampin resistant by MTBDRplus and fluoroquinolone susceptible by MTBDRsl HIV seropositive (with or without antiretroviral therapy) or negative (but not unknown) and Karnofsky score of >60 at sites in Moldova, Peru, and the Philippines. Patients with MDR-TB will be randomized to oral regimen of delamanid (DLM), linezolid (LZD), levofloxacin (LFX) and pyrazinamide (PZA) for 24, 32, 40, 48 or 56 weeks or World Health Organization (WHO) standard of care MDR-TB regimen (9-month "modified Bangladesh" regimen or WHO standard MDR-TB regimen). Primary Objective 1. Determine the shortest duration of the delamanid-containing oral regimen that is non-inferior to the blended WHO standard regimen. Secondary Objective 1. Define the safety and tolerability of the oral delamanid, linezolid, levofloxacin and pyrazinamide regimen. 2. Determine if baseline PZA susceptibility is associated with shorter time to non-inferior treatment duration. 3. Identify the relationship between delamanid and linezolid serum drug levels and time to sputum culture conversion among patients on the delamanid-containing oral regimen. 4. Identify the relationship between delamanid and linezolid serum drug levels and occurrence of adverse events among patients on the delamanid-containing oral regimen.

NCT ID: NCT02974777 Withdrawn - Clinical trials for Platelet Dysfunction Due to Drugs

The IDEAL-PCI Extended Registry

IDEAL-PCI ext
Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer). IDEAL-PCI Extended is the continuation of the IDEAL-PCI registry with additional focus on bleeding events and net clinical benefit

NCT ID: NCT02973295 Withdrawn - Clinical trials for Non-Alcoholic Fatty Liver Disease

Silymarin in NAFLD

SINF
Start date: September 20, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates the influence of Silymarin in reducing laboratory, ultrasonographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive Silymarin (Verum) while the other half will receive placebo

NCT ID: NCT02973191 Withdrawn - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia

ORBIT
Start date: December 20, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, multi-center, open-label, Phase 2 study to determine the efficacy and safety of JCAR015 in adult subjects with B-cell ALL. The study is divided into two sequential parts, Part A and Part B; subjects will be screened and will provide informed consent before initiating any study procedures in Part A of the study.